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Abstract
As essential components of the regulatory system of gene expression, microRNAs
(miRNAs) have been shown to influence development, severity, prognosis, and/or
progression of a variety of inherited diseases. Differential expression studies have
evidenced an impact of miRNAs on lung disease development in chronic obstructive
pulmonary disease (COPD), asthma, lung inflammation, consequences of smoke
exposure and airway allergy in human and in animal models of the diseases. Recent
clinical and cell-based studies have revealed specific alterations of miRNA expression
in cystic fibrosis (CF). Here we critically review the major findings concerning altered
miRNA expression in CF airway epithelium, in particular with respect to CF
transmembrane conductance regulator (CFTR) expression, innate immunity, and
epithelial differentiation. Finally, we explore strategies to exploit these changes with
the aim of innovative therapeutic benefits.
Keywords: microRNA, cystic fibrosis, CFTR, lung pathophysiology, inflammation, epithelial
differentiation, biomarkers
1. Introduction
Cystic Fibrosis (CF) is due to mutations in the CF transmembrane conductance regulator
(CFTR) gene causing impairment of chloride ions exchanges through the apical membrane of
epithelial cells. CF affects epithelia in a variety of organs, notably lung, intestine, pancreas and
the reproductive system. The most common CFTR mutation, F508del, results in deletion of a
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phenylalanine at position 508 of the protein, and the mutated protein is retained in the
endoplasmic reticulum and rapidly degraded via the endoplasmic reticulum-associated
degradation pathway. Up to now, almost 2000 CFTR mutations have been identified (http://
genet.sickkids.on.ca). A good correlation can generally be observed between CFTR genotype
and the gastrointestinal disease, the pancreatic status, and the reproductive tract abnormali‐
ties, but the lung disease outcome is difficult to predict based solely on CFTR genotype (http://
www.cftr2.org/). For example, it has been shown that siblings and monozygous twins, thus
carrying the same CFTR genotype, even if living in the same environment and receiving the
same medical care, may develop different spatial and temporal patterns in lung disease
progression. The basis for variability in severity of CF lung disease is poorly understood and
depends on concomitant expression of other genetic and environmental factors. Over the
recent years, exploring the role of genetics/genomics (e.g. modifier genes, gene-environment
interactions, epigenetics, etc.) has received growing attention in CF, with the aim of unveiling
basic mechanisms and bringing in better understanding of the pathophysiology of the disease,
helping to predict its progression, and hopefully leading to specially designed novel thera‐
peutic strategies.
Of the whole human genome, only a small fraction, the protein-coding part, has long attracted
attention because of the pervasive role of genes in determining amino acid sequences of
expressed proteins, leading to observable consequences of mutations. Later on, following the
discovery of transduction factors regulating gene translation, the initial view of “junk DNA”,
corresponding to the majority of DNA, had to be revisited. Following the identification of non-
messenger RNA functions, the new concept of a network of non-coding transcriptome that
regulates protein-coding expression emerged.
Non-coding RNAs are presently broadly categorized into three classes. The major class (well
over 90% of total RNA) makes up the so-called housekeeping RNAs; they consist of small
nuclear, small nucleolar, transfer, and ribosomal RNAs, the latter interacting with protein and
transfer RNA to form the functional ribosome complex. The other classes of non-coding RNAs
are long (>200) and short (<200) ribonucleotides. The best characterized and most extensively
studied family of non-coding RNAs is that of microRNAs (miRNAs), short (17--27 nucleotides
in length) single-stranded RNA molecules, which negatively regulate the translation of
messenger RNAs into proteins. Figure 1 summarizes the general mechanism of biogenesis of
miRNAs. Highly phylogenetically conserved, they bind to the 3’UTR (untranslated region) of
target mRNAs, thereby potently repressing the target mRNA translation into protein or
favoring mRNA degradation. To date, more than 1800 mature miRNAs have been identified
in the human genome (http://www.mirbase.org). Bioinformatics studies predict that miRNAs
potentially regulate the expression of about 60% of human genes.
As essential components of the regulatory system of gene expression, miRNAs have been
shown to influence the development, the severity, the prognosis and/or the progression of a
number of inherited diseases [1]. Differential expression studies of miRNAs have evidenced
an impact on lung disease development in chronic obstructive pulmonary disease (COPD),
asthma, lung inflammation, consequences of smoke exposure and airway allergy in human
and in animal models of the diseases [2]. Since marked inflammation is a major feature of CF
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lung disease, miRNAs may be expected to play a role in its pathogenesis. Indeed, recent clinical
and cell-based studies have revealed CF-specific alterations in miRNA expression. This point
will be extensively discussed further below.
In this article, we review and highlight some of the most relevant published data focusing on
miRNAs in CF. The first section deals with regulation of CFTR expression and modulation of
CFTR trafficking. In the second section, key elements of inflammatory and innate immune
responses in with CF airways are reviewed, focusing on the potential role of miRNAs in
molecular pathways involved in lung inflammation. The third section discusses the potential
role of miRNAs in lung development, differentiation and remodeling. The next section
explores strategies to exploit miRNAs as biomarkers and potential therapies of CF disease.
Finally, limitations in translating miRNAs from deeper knowledge of their role in pathogenesis
to development of new therapies are highlighted.
2. Regulation of CFTR expression
The human CFTR gene is located on chromosome 7 and spans 189 kb. Its mRNA transcript is
6.2kb long and includes a 1.5kb 3’UTR containing multiple potential binding sites for miRNAs.
Figure 1. Biogenesis of microRNAs (miRNAs). miRNA genes are transcribed by RNA-polymerase 2 into primary mi-
RNA (pri-miRNA) precursors. The pri-miRNAs are cleaved in the nucleus by a nuclear protein complex including the
class 2 ribonuclease III Drosha to produce pre-miRNAs. Pre-miRNAs are exported to the cytoplasm via the nuclear
export protein Exportin. In the cytoplasm, a pre-miRNA is cleaved by a protein complex including the helicase Dicer
and form a duplex of miRNAs containing the mature miRNA bound to its complementary sequence (miRNA*). Du‐
plexes are unwound and mature miRNAs bind to the 3’UTR of the target mRNA within the RNA-induced silencing
complex to prevent translation by inhibition of ribosomes binding or mRNA degradation.
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According to computational analyses using common bioinformatic programs such as Tar‐
getScan (http://www.targetscan.org), PicTar (http://pictar.mdc-berlin.de), and miRanda
(http://www.microrna.org), CFTR 3’UTR contains almost 500 putative miRNA target sites,
several of which have already been examined.
The main miRNAs involved in cystic fibrosis pathogenesis are summarized in figure 2.
Gillen et al. were the first to experimentally show that miRNAs could regulate CFTR expression
[3]. Among the numerous miRNAs putatively repressing CFTR mRNA, twelve miRNAs
(miR-145, miR-331-3p, miR-376a/b, miR-377, miR-384, miR-494, miR-600, miR-607, miR-939,
miR-1246, miR-1290 and miR-1827) were able to decrease CFTR mRNA levels in the human
Bronchial epithelial (HBE) 16HBE-14o-, colon carcinoma epithelial Caco-2 and the pancreatic
adenocarcinoma PANC-1 cell lines. Direct targeting of the CFTR 3’UTR was evidenced for
miR-145 and miR-494 in Caco-2 cells. The results [3] showed that the pattern of miRNAs effects
on targeted CFTR 3’UTR varies with cell lines, suggesting that miRNA-driven gene expression
could be tissue specific. Another study [4] demonstrated direct repression of CFTR expression
by miR-101 and miR-494 in the HEK (human embryonic kidney) cell line expressing CFTR
3’UTR constructs. miR-101 and miR-494 seem to bind directly to the CFTR 3’UTR at positions
1508–1514 and 1140–1147, respectively. Downregulation of CFTR gene expression by miR-101
as well as by miR-144 and miR-145 was further confirmed in the 16HBE14o- cell line and in
primary human airway cells, which are relevant models of CF lung disease [5, 6].
In a non-CF context, expression of miR-101 and miR-144 was previously shown to be upre‐
gulated in lungs upon exposure to air pollutants (such as cigarette smoke or cadmium) and
correlated with loss of CFTR expression [4]. Hassan et al. [5] demonstrated upregulation of
miR-101 in vivo in mice exposed to cigarette smoke, a condition associated with acquired loss
of CFTR function [7]. miR-101 was also found highly expressed in lungs of COPD smoking
patients in comparison with that of healthy non-smoking subjects. Moreover, miRNA expres‐
sion profile analysis performed in the CF bronchial brushings in comparison to healthy
controls showed high levels of miR-101, thus further reinforcing the potential role of miR-101
in CF [8]. Interestingly, synergistic effects between miR-101 and miR-494 were observed,
although they are targeting different sites in CFTR 3’UTR [4]. Similar synergy was found for
miR-509–3p and miR-494 [9]. Therefore, distinct miRNAs may act cooperatively to regulate
CFTR expression and function in primary airway epithelial cells.
These miRNAs are likely able to modulate F508del-CFTR mRNA expression as well. Interest‐
ingly, increased expression of miR-145, miR-223 and miR-494 in vivo has been shown to
correlate with decreased CFTR expression in bronchial epithelium of individuals bearing the
F508del-CFTR mutation [3] as well as in CFBE41o- cells [10]. Experimental modulation of
miRNA expression confirmed the hypothesis supporting the view that deregulation of miRNA
may affect CFTR biogenesis in CF cells. Another study demonstrated that miRNA can
indirectly influence CFTR biogenesis by modulating expression of other regulatory elements
such as transcription factors [11]. It has been shown that modulating the transcription
regulation factor SIN3A expression with miR-138 mimics increased biogenesis and cell surface
expression of both wild-type and F508del-CFTR proteins. Interestingly, miR-138 indirectly
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prevented proteosomal degradation of F508del-CFTR mutant and favored its trafficking
towards the apical membrane in HBEs from CF patients [11].
Altogether, these data are in favor of a role for several miRNAs in the post-transcriptional
regulation of the CFTR channel synthesis and trafficking. Because several of them are deregu‐
lated in CF, they could play a major role in CF lung pathology.
3. Regulation of key elements of inflammation and innate immune system
miRNAs are crucial regulators of innate and adaptive immune responses and their abnormal
expression or function or both have been linked to multiple human inflammatory disorders
[12]. The link between CFTR mutations and the mechanisms underlying disproportionate
proinflammatory responses remains poorly understood. Aberrant release of proinflammatory
mediators by epithelial and immune cells in CF includes hypersecretion of interleukin-8 (IL-8).
The fact that this can be detected in lungs of children with CF [13] even during fetal life [14,
15] suggests that it is a constitutive process of CF. miRNA-based post-transcriptional regula‐
tions, known to be highly sensitive to a range of homeostasis signals, such as changes in
hypoxia, pH, ion concentration and osmolarity, have recently been considered as potentially
regulating immune responses in CF, and more specifically IL-8 hyperproduction.
The first published contribution of miRNA involvement in CF [8] reported that miR-126 was
found to be abundantly expressed in normal lungs and that it was reduced in lungs of patients
with CF. This process cannot account for the pathophysiological mechanism of changes
observed in patients with CF, based on the observation of high concentrations of IL-8 depend‐
ing on constitutive activation of nuclear factor kappa B (NF-κB) [15-17]. Indeed, Oglesby et al.
[8] found that in patients with CF, miR-126 was strongly downregulated and expression of
TOM1, which is itself a negative regulator of the NF-κB signaling pathway, was upregulated.
On this basis, a decreased expression of IL-8 would be expected, in contradiction to the well-
established increased IL-8 production. These observations indicate that miR-126 alone does
not play a role via the TOM1 cascade and that other factors may also be involved. Other
miRNAs originated from host or part of this microbioma could also be involved. For example,
Rao et al. [18] reported their finding of bacterial miR-146, which binds to a receptor of the TLR
family, in sputum of CF patients infected with Pseudomonas aeruginosa.
As for other miRNAs, it has been suggested that expression of miR-155 might contribute to
the activation of IL-8--dependent inflammation in patients with CF. Clinically, overexpression
of miR-155 has been observed in lung epithelial cells and in neutrophils from patients with CF
[18]. Interestingly, miR-155 expression was also elevated in primary CF bronchial epithelial
cells and in IB-3 and CuFi-1 CF cell lines [16, 19]. Upregulating miR-155 expression in these
cells increased production of IL-8 through activation of the PI3K/Akt signaling pathway [16].
Another study confirmed these results [17] by showing that high levels of miR-155 in sterile
CF cells, reduced after exposure to the anti-inflammatory cytokine IL-10 or following inhibition
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of IL-1β signaling, was accompanied by a reduction of IL-8 production. These observations
suggest a general role of miR-155 as an IL-8 expression regulator and consequently of the NF-
κB pathway [16, 17, 19, 20]. The expression of miR-155 is also increased in patients with asthma,
idiopathic pulmonary disease and acute lung injury [21]. It has been underlined that a tight
control is required for the expression of a molecule such as miR-155 which is overexpressed
in cancers of B-cell origin. It is noteworthy that a signaling molecule as small as miR-155 has
such a dangerous potential when deregulated.
Although so far, few studies have focused on the role of miRNA as regulator of the immune
response specifically in the CF context, it is of prime importance to consider other miRNAs,
the expression of which is deregulated in inflammatory lungs, and which could be non-
specifically modulated in CF. CF cells display a new profile of miRNAs, including high
expression of miR-215 which is a strong modulator of cell cycle through the p53-signaling
pathway [17]. As an example of unspecific modulation, miR-509-3p and miR-494 (which
directly target CFTR expression, as described above) are overexpressed in CF bronchial
epithelial cells [9]. In addition, bacterial infection and tumor necrosis factor-alpha and IL-1β
exposure increase miR-509–3p and miR-494 concentrations in part via the action of the NF-kB
transcriptional activator complex. These findings, together with those showing that miR-494
is upregulated in CF cells [9, 10], support the idea of a role of miRNAs in inflammatory
responses in CF respiratory epithelia, either directly by activation of transcription factors such
as NF-κB, or indirectly by inhibition of CFTR expression.
Another crucial aspect of the immune response in lungs of patients with CF is the dysregulation
of the protease-antiprotease balance which eventually leads to bronchiectasis [22]. Much
attention has been given to serine proteases, in particular elastase secreted by neutrophils
massively recruited during lung inflammation in patients with CF. However, other proteases
secreted by epithelial cells themselves impact airway function. Recently, involvement of
cysteine proteases cathepsin (CTS) B and S, overexpressed in lungs of patients with CF, has
been described [23]. CTSS is constitutively released at high levels by airways of patients with
CF. Weldon et al. showed that the overproduction of CTSS in lungs of patients with CF was
indirectly modulated by miR-31 in HBEs via repression of the transcription factor, interferon
regulatory factor 1 (IRF1), which directly controls the CTSS gene [24]. It could be predicted
that evidence will be brought up, showing that other proteases, such as metalloproteinases,
often detected at high levels in CF patients sputum, are also regulated by miRNA-dependent
mechanisms. Similarly, miRNAs could be involved in the expression of anti-proteases (e.g.,
α-1 antitrypsin, secretory leucocyte protease inhibitor (SLPI), tissue inhibitors of metallopro‐
teinase 1 (TIM-1)), opening new perspectives in development of novel therapies for CF and
other lung diseases.
It is quite likely that a number of miRNAs could find several target points in the network of
cellular and molecular players of the inflammation, imbalanced in CF. In turn, inflammatory
responses themselves drive the expression of several miRNA species that either worsen the
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imbalance by increasing production of proinflammatory mediators or directly repress CFTR
protein expression, forming a vicious circle.
4. Regulation of lung cell development and differentiation
Studies of miRNAs expression patterns have revealed that 27 miRNAs are differentially
expressed during lung embryogenesis [25] following a characteristic pattern. miR-29a is highly
expressed in late stages of lung development and in adult life [26]. In contrast, the miR-17-92
locus is highly expressed in undifferentiated lung epithelial cells and in lung cancer cells [27],
and its expression progressively declines as differentiation progresses. Interestingly, miR-127
and miR-351 are transiently expressed during late phases of lung embryogenesis, first in the
mesenchymal network, and then in epithelial cells. These observations suggest that miRNAs
play distinct roles in the differentiation processes during the mesenchymal-to-epithelial
transition.
The chronic inflammation in CF leads to irreversible airway tissue remodeling characterized
by loss of multiciliated cells, gain in mesenchymal cells, goblet cells hyperplasia, and squamous
metaplasia. Two miRNAs involved in multiciliogenesis have particularly attracted attention.
miR-449a accumulates in bronchial epithelial cells during their transition to full differentiation
[28]. Involvement of this particular miRNA in multiciliogenesis has been previously described
[29]. Expression of miR-449a remains high in differentiated cells, indicating that it also plays
a role in maintaining the multiciliated phenotype [29]. Conversely, expression of miR-455-3p,
which negatively regulates the mucin 1 gene, is lost during the differentiation process of HBEs,
reinforcing the control of epithelial (de)differentiation by miRNAs. Consequently, high
expression of miR-449a and low expression of miR-455-3p can serve as biomarkers for the
differentiation of bronchial epithelia. Further studies would be welcome to determine whether
these miRNAs are deregulated in CF cells.
Airway epithelium dedifferentiation is part of tissue remodeling through induction of
epithelial-mesenchymal transition (EMT). EMT is a process during which epithelial cells lose
their phenotype, including loss of cell polarity and dissolution of cell-cell junctions, and
acquire mesenchymal characteristics. Transforming growth factor (TGF)-β is a key mediator
of EMT and epithelial remodeling. TGF-β signaling was shown to be increased in CF lungs [30]
and several miRNAs are regulated via the TGF-β pathway [31]. Among them, miR-155
expression is reduced in human fibroblast cells upon exposure to TGF-β [32]. Although it may
contribute to reduce inflammation (through its effect of IL-8 secretion in HBEs described
earlier), reduction of miR-155 expression at the airway level might contribute to loss of
epithelial polarity. Moreover, another study utilizing epithelial cells indicated that miR-155
plays an important role in TGF-β-induced EMT as it facilitates tight junction dissolution [33].
Because CFTR expression is important to maintain epithelial differentiation and polarity [34],
in particular in CF cells [35], it could be expected that at least some of the other miRNAs
controlling CFTR expression might be involved in airway remodeling as well. Likewise, other
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miRNAs might non-specifically regulate epithelial differentiation in CF cells and could be
involved in loss of epithelial polarity.
Figure 2. Main miRNAs involved in cystic fibrosis pathogenesis The left part depicts miRNA-dependent regulation of
cystic fibrosis transmembrane conductance regulator (CFTR) biogenesis and trafficking. The right part zooms into the
regulation of interleukin (IL)-8 production by miRNAs. miRNAs which may drive phenotypic changes on multicilio‐
genesis, airway remodeling and disorganization of tight junction are also represented. Red arrows depict changes re‐
ported in CF; up arrows indicate upregulated miRNAs and phenotype; and down arrows indicate miRNA and
phenotype downregulation. CSE: cigarette smoke exposure; CTS: cathepsin.
MicroRNAs  potentially  altered  and  phenotypic  consequences  in  CF  are  summarized  in
Table 1.
Target MicroRNA Expression Consequences References
CFTR miR-101, -144,
-494
Overexpressed in CF nasal and
bronchial biopsies
Downregulation of CFTR
expression
4,5,7,8,10
CFTR miR-145,-223,
-494, 509-3p
Overexpressed in CF bronchial
brushings and CFBE41o- cell line
Downregulation of CFTR
expression
3,5,9,10
SIN3A miR-138 Corrector of CFTR trafficking
Inhibition of proteosomal
degradation of F508del-CFTR, Cl-
permeability
11
TOM1 miR-126 Decreased expression in CF
bronchial brushing and CFBE41o-
cell line
Unexplained downregulation of
NF-κB
8
Cystic Fibrosis in the Light of New Research240
Target MicroRNA Expression Consequences References
SHIP1 (Pi3K/
Akt)
miR-155, -125 Overexpressed in CF neutrophils, in
primary CF bronchial epithelial cells
and in CF cell lines (IB-3 and CuFi-1)
IL-8 hyperproduction
NF-κB activation
Proapoptotic p53-signalling
pathway
EMT via TGF-β signalling
16,17,19,20,
32,33
IRF-1 miR-31 Decreased expression in CF
bronchial brushing
Cathepsin S hyperproduction 24
miR-29a Highly expressed in late stages of
lung development and in adult life
Lung embryogenesis 26
miR-127, -351 Transiently expressed during late
phases of lung embryogenesis
Modulation of lung development 25
miR-17-92 Highly expressed in undifferentiated
lung epithelial cells
EMT 27
miR-449a Accumulated in bronchial epithelial
cells
Multiciliogenesis, EMT 28,29
MUC1 miR-455-3p Expressed in human bronchial
epithelial cells
EMT
negative regulation of mucin 1
29
EMT = epithelial mesenchymal transition
Table 1. microRNAs potentially altered and phenotypic consequences in cystic fibrosis (CF)
5. miRNAs as biomarkers and potential therapies
As in other diseases in which miRNAs have been involved, such as asthma, COPD, idiopathic
pulmonary fibrosis, cancer and diabetes, further analyses of miRNA expression-function
relationships will very likely reveal new genetic factors that could be targeted in therapy. There
is also a great hope that miRNAs could be used as diagnostic markers and represent new
prognostic factors that might influence the course of the CF disease.
The pathophysiology of CF is very variable from patient to patient and is only partly explained
by the CFTR genotype. Two recent studies raised the hypothesis that profiling serum miR‐
Nome could identify miRNAs as potential prognostic biomarkers [16, 36]. First, elevated
miR-155 serum levels have been detected in patients with CF, possibly reflecting its high
expression in CF airway cells [16]. Second, a prototype study by Cook et al. has suggested that
serum miRNAs could be used as diagnostic markers in CF liver disease [37]. Profiles of
circulating miRNA levels in patients with CF liver disease were compared to those of CF
patients without liver disease and of non-CF controls. For the first time, changes in circulating
miRNA levels were identified in CF and they were correlated with disease status, suggesting
that serum miRNA analysis may help predict early onset of hepatic fibrosis in CF [36]. It could
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be expected that new biomarkers of the course of the CF lung disease will be identified in the
coming years.
It can also be foreseen that single nucleotide polymorphisms (SNPs) in the 3’UTR of miRNA-
targeted genes, in particular CFTR, may explain phenotype variability. As an illustration, an
SNP (c.*1043A>C) was identified in the 3’UTR of CFTR in a patient with a CFTR-related disease
[38]. CFTR-related diseases are clinical entities associated with CFTR dysfunction but that do
not fulfil diagnostic criteria for classical CF (e.g., Congenital Bilateral Absence of Vas Deferens
(CBAVD), chronic pancreatitis and disseminated bronchiectasis). This SNP was located within
the binding site of two miRNAs including miR-509-3p (shown otherwise to directly target
CFTR mRNA), and experimental data suggested that it might impair the regulation of gene
expression. That could explain the mild phenotype, as this SNP would act as a mild mutation.
Consequently, polymorphisms in the CFTR 3’UTR may play a role in the observed heteroge‐
neous phenotype. Molecular analysis of the 3’UTR of CFTR could therefore be performed as
a differential diagnostic tool in patients presenting with suggestive clinical symptoms of CF
but no mutation in the CFTR gene per se.
Modulating miRNA expression in vivo looks very appealing for developing new CF therapies
[38]. Indeed miRNAs are short and need to be delivered only to the cytoplasm, as opposed to
nucleus delivery required for DNA-based constructs. Moreover, miRNA-based therapies have
several advantages over gene therapy strategies aiming at restoring CFTR expression. First,
miRNA modulators are likely to target multiple genes in the context of a deregulated network.
However, this might also be a major drawback as potential off-target effects may cause adverse
phenotypes. Second, as in all cases of gene therapies, tissue-specific delivery remains a major
issue in miRNA-based therapies. An interesting approach has been used by McKiernan et al.
to successfully deliver miRNA replacement therapy in CFBE41o- cells [39]. They demonstrated
that polyethyleneimine nanoparticles complexed with pre-miR-126 resulted in significant
knock-down of TOM1, previously described as a direct target of miR-126 [8]. This result shows
that polymeric nanoparticles may be used to effectively deliver miRNA replacement therapy
with no adverse effects and may present a strong advantage in comparison to virus-based
delivery strategies. As for any other disease for which miRNA-based therapy is considered as
an attractive new option, factors controlling the stability of the miRNAs, the delivery systems
and the off-target effects of miRNA-based therapies represent strong challenges for the future
of development of such drugs.
6. Limitations in translating miRNAs from deeper knowledge of their role
in pathogenesis to development of new therapies
Altogether, it is crucial to highlight important experimental considerations regarding miRNA
investigations in CF. Expression profiles of miRNAs in human CF bronchial tissue often differ
from study to study. The differences can be explained in part by the selection of tissue material.
Indeed, the presence of inflammatory cytokines or non-resident, migratory cells (neutrophils,
macrophages, etc.) or both infiltrating airway epithelium generate a non-negligible degree of
heterogeneity in biopsy samples. Similar issues can be faced when analyzing miRNA expres‐
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sion in human primary HBEs cultures. miRNA expression is strongly dependent on cell origin
and differentiation state and on culture conditions. Accordingly, the air-liquid interface
condition, which favors differentiation towards the epithelial phenotype, might influence
miRNA expression. Moreover, although cultured, undifferentiated HBEs are quite homoge‐
nous, when switching to air-liquid interface condition, not only ciliated cells but also basal and
goblet cells are found. In summary, any heterogeneity in cell population is likely to bring bias
in miRNA expression profiles.
The large discrepancy among miRNA studies on CF disease may also indicate tissue- or organ-
specific expression patterns of miRNAs [40]. Consequently, miRNA gene targeting may be
variable in different tissues and organs as well. This point is particularly relevant in CF, a
multisystemic disease. Similarly, studies aimed at profiling miRNAs in established CF mouse
models may show differences that could be species specific. Substantial differences in technical
approaches and statistical analyses are also important factors of variability and lack of
reproducibility among studies.
Moving towards translation from bench to bedside, practical limitations including degradation
and inactivation by nucleases, efficacy of intracellular delivery, short plasma elimination rates,
renal and dose-limiting hemodynamic toxicities may hamper development of miRNA-based
therapies. As miRNAs have pleiotropic intracellular effects on multiple signal transduction
pathways, either single or combined therapies targeting CFTR expression, modulation of
inflammation and cell differentiation might eventually be considered. This development could
prove lengthy and full of traps and pitfalls before reaching a stage of translation to the clinical
setting.
7. Conclusion
The study of miRNA in CF is still at an embryonic stage. To date, several studies have
determined profiles of miRNAs in samples from target tissues such as lung and nasal biopsies,
primary bronchial epithelial cell cultures or epithelial tissues from relevant mouse models.
They have generated some indirect data suggesting a significant role of miRNA in controlling
lung development, CFTR expression, as well as inflammation signaling pathways in CF.
The preliminary findings reviewed here form a solid basis for growing interest in miRNAs in
CF. The possibility that they may act as phenotype modifiers and that they could be used as
diagnostic and prognostic biomarkers looks very attractive. With no doubt, further research
on miRNA biogenesis and function in CF will expand widely in the coming years, shedding
new light on disease variability and paving the way to innovative therapies.
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